April 4, 2017 / 11:10 AM / 4 months ago

BRIEF-Abbvie submits supplemental new drug application for ibrutinib

1 Min Read

April 4 (Reuters) - Abbvie Inc-

* Abbvie announces ibrutinib (imbruvica®) supplemental new drug application for previously treated chronic graft-versus-host-disease (cgvhd) accepted for review by U.S. FDA

* Abbvie Inc says imbruvica is jointly developed and commercialized by Pharmacyclics Llc, an Abbvie company, and Janssen Biotech, inc Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below